#1
#1 out of 125.00%
health2h ago
Alzheimer's Awareness Month: The Science Is Moving Fast
- Latest development: FDA-approved antiamyloid therapies can slow cognitive decline by 25% to 30%.
- APOE e4 variant remains the key genetic risk factor for late-onset Alzheimer's.
- Two copies of APOE e4 may raise side-effect risk from treatments like brain swelling or bleeding.
- Blood tests now help identify Alzheimer’s biomarkers earlier and less invasively.
- Lifestyle measures like exercise, diet, and cognitive training may influence risk.
- Vaccines such as shingles and RSV may be linked to lower dementia risk.
- Genetic testing for APOE is optional and individuals can choose their level of information exposure.
- Alzheimer’s research is at an inflection point with momentum and hope.
- The APOE e4 risk context is evolving with studies showing nuanced impacts across variants.
- Researchers see a potential for prevention strategies tailored to APOE results.
Vote 0